The Uterine Cancer Study Act of 2024 directs the Secretary of Health and Human Services to conduct a comprehensive study examining the relationship between chemical hair straighteners and uterine cancer, with particular focus on women of color who experience higher rates of this disease. The study will review existing research, analyze how different types of hair straighteners such as those containing dyes, bleach, or perms may affect cancer risk across various racial and ethnic groups, and determine whether the Food and Drug Administration should require additional safety testing for these products. The legislation requires the agency to submit a description of its study methodology within 45 days of the bill's enactment, begin the study within 180 days, and deliver a final report within two years. No specific funding amount is identified in the bill, though it coordinates the efforts of the FDA and National Institutes of Health alongside HHS. This legislation responds to emerging health concerns about chemical hair care products and their potential health risks, particularly for communities that use these products more frequently.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.